Plasmodium berghei bio-burden correlates with parasite lactate dehydrogenase: application to murine Plasmodium diagnostics by Sai Lata De et al.
De et al. Malar J  (2016) 15:3 
DOI 10.1186/s12936-015-1027-2
METHODOLOGY
Plasmodium berghei bio-burden 
correlates with parasite lactate dehydrogenase: 
application to murine Plasmodium diagnostics
Sai Lata De1, Danielle I. Stanisic1, Fabian Rivera2, Michael R. Batzloff1, Christian Engwerda2 and Michael F. Good1*
Abstract 
Background: The spectrum of techniques to detect malaria parasites in whole blood is limited to measuring 
parasites in circulation. One approach that is currently used to enumerate total parasite bio-burden involves the use 
of bio-luminescent parasites. As an alternative approach, this study describes the use of a commercial ELISA human 
parasite lactate dehydrogenase (pLDH) detection kit to estimate total parasite bio-burden in murine malaria models.
Methods: The cross reactivity of pLDH in a commercial human malaria pLDH diagnostic kit was established in differ-
ent components of blood for different murine malaria models. The use of pLDH as a measure of parasite bio-burden 
was evaluated by examining pLDH in relation to peripheral blood parasitaemia as determined by microscopy and 
calculating total parasite bio-burden using a bio-luminescent Plasmodium berghei ANKA luciferase parasite.
Results: The pLDH antigen was detected in all four murine Plasmodium species and in all components of Plasmo-
dium-infected blood. A significant correlation (r = 0.6922, P value <0.0001) was observed between total parasite bio-
burden, measured as log average radiance, and concentration of pLDH units.
Conclusions: This high throughput assay is a suitable measure of total parasite bio-burden in murine malaria infec-
tions. Unlike existing methods, it permits the estimation of both circulating and sequestered parasites, allowing a 
more accurate assessment of parasite bio-burden.
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Background
Malaria continues to be a leading cause of mortality in 
endemic countries, despite control and eradication initia-
tives, such as the use of insecticide-treated bed nets and 
anti-malaria drug treatment [1]. Clinical disease typically 
presents as fever, chills, severe headache, and vomiting, 
and requires a prompt diagnosis followed by effective 
treatment to ensure resolution of the infection. Impor-
tantly, disease outcomes are directly correlated with total 
parasite burden [2]. In rodent malaria models, Giemsa-
stained blood films (the gold-standard microscopy tech-
nique) [3, 4], PCR [5], flow cytometry [6, 7], fluorescent 
[8, 9] or DNA/RNA [10–12] markers and radioisotope 
labelling [11] have been used to measure parasitaemia in 
in vivo preclinical efficacy studies for anti-malaria drugs 
and vaccine candidates. However, these approaches are 
limited to detecting circulating parasites and do not 
account for sequestered parasites, which is important for 
determining total parasite bio-burden. Bio-luminescence 
imaging, using transgenic parasite that express the fire-
fly luciferase reporter protein, has been used not only 
to measure parasite growth in vivo and in vitro [10], but 
also to visualize in vivo the parasite sequestration in deep 
tissues [13–16].
Various assays using specific antibodies to parasite 
antigens have been employed [17–24]. Immunochro-
matographic assays, which utilize monoclonal antibod-
ies against specific Plasmodium enzymes, are under 
development. The most promising antigens explored 
so far include: histidine rich protein-2 (HRP-2) [25], 
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parasite-specific lactate dehydrogenase (pLDH) [18, 19, 
26–28], and aldolase [29, 30]. These enzymes are involved 
in metabolic pathways essential for the growth and sur-
vival of Plasmodium parasites [29].
The enzyme pLDH is a soluble, energy-producing 
enzyme that is involved in the last step of the glycolytic 
pathway [29]. As the red blood cells do not have func-
tional mitochondria and the parasites have minimum 
oxygen uptake for the citric acid cycle [31], it is highly 
dependent on anaerobic glucose metabolism [32, 33]. 
pLDH is produced by both asexual blood-stage para-
sites as well as the sexual stages, with a larger quantity 
of pLDH being produced during the asexual stage [29]. 
pLDH antigen is preferable as a diagnostic marker over 
other antigens such as HRP-2, which is limited to Plas-
modium falciparum only [34]. Moreover, some P. falcipa-
rum strains have a deletion in the HRP-2 gene, resulting 
in false negative tests [35]. Unlike HRP-2, pLDH does not 
persist in the blood [36, 37] and is cleared immediately 
post-active infection [18–20, 22, 38, 39], thus making 
pLDH an ideal marker to estimate parasite bio-burden at 
the time of the assay.
Previously, monoclonal antibodies specific for pLDH 
have been used to determine the sensitivity of Plas-
modium berghei to anti-malarial drugs in  vitro [40]. A 
chromogenic pLDH assay has also been employed to 
enumerate the parasites in the blood of mice challenged 
with Plasmodium yoelii 17XNL post vaccination with 
MSP1-19 [41]. However, none of these approaches was 
compared to an established assay to quantify and validate 
total parasite bio-burden.
The pLDH amino acid sequence has a 90  % sequence 
identity amongst all human Plasmodium species [33, 42]. 
For human parasites, monoclonal antibodies against the 
shared common epitopes can be used to detect all species 
[43, 44]. Genetic conservation and variation of pLDH 
across different human and rodent species and strains of 
Plasmodium was reported by Talman et  al. [45]. Nucle-
otide BLAST analysis using 951 nucleotides of the P. 
falciparum 3D7 (Pf LDH) gene coding sequence [Acces-
sion ID XM_001349953.1] as the reference revealed 
the following per cent identity in different species of 
murine Plasmodium: 86 % identity with P. yoelii 17XNL 
[Accession ID XM_719008.1]; 85  % with Plasmodium 
chabaudi chabaudi [Accession ID XM_740087.1]; 85  % 
with P. berghei ANKA [Accession ID XM_674309.1]; 
and 83  % with Plasmodium vinckei [Accession ID 
XM_008624100.1]. The high degree of sequence similar-
ity could potentially be exploited for use in diagnostics 
for rodent malaria parasites (Table 1).
This study investigated the use of a commercial human 
Plasmodium pLDH ELISA diagnostic kit for detect-
ing pLDH antigen as a measure of parasite bio-burden 
during murine malaria infections. This assay could be 
established as an alternative approach to measure para-
site bio-burden in efficacy studies.
Methods
Mice and ethics statement
Female BALB/c mice aged 4–6 weeks were purchased 
from the Animal Resource Centre (ARC) (Canning Vale, 
Perth, Australia) and maintained under appropriate ARC 
and Griffith University conditions. This study was car-
ried out in strict accordance with the National Health 
and Medical Research Council of Australia guidelines, as 
detailed in the document, Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes, 8th 
ed [46]. The Griffith University Animal Ethics Commit-
tee (GLY/05/12/AEC) and the QIMR Berghofer Medi-
cal Research Institute Ethics Committee (A02633M) 
approved the relevant animal procedures and protocols.
Parasites and infections
Cloned lines of P. chabaudi AS, P. yoelii 17XNL, P. yoe-
lii YM, P. berghei and P. vinckei were used (provided by 
Richard Carter, University of Edinburgh, UK). Stabilates 
were maintained by intra-venous (IV) and intra-peri-
toneal (IP) passaging of 106 parasitized red blood cells 
(pRBC) into naïve BALB/c mice. Plasmodium berghei 
ANKA luc lines (provided by Chris Janse, Leiden Univer-
sity Medical Centre, The Netherlands) were used in the 
bio-luminescent experiments for in  vivo imaging after 
one in vivo passage in mice.
Evaluation of parasitaemia by microscopy
Thin blood smears were prepared, air dried, fixed in 
methanol and stained with Giemsa. Slides were exam-
ined using bright field microscopy and counts were per-
formed with 100× magnification. For negative or low 
parasitaemia films (<1  %), at least 20 fields on the slide 
were counted. For high parasitaemia, at least 500 RBCs 
were counted. Percent parasitaemia was calculated as the 
number of pRBCs multiplied by 100 divided by the num-
ber of total RBCs.
Assessment of pLDH antigen production in murine malaria 
models
Qualitative and quantitative levels of pLDH antigens 
in BALB/c mice infected with P. chabaudi AS, P. yoelii 
17XNL, P. yoelii YM, P. berghei ANKA, and P. vinckei 
were determined using the pLDH SD Malaria Antigen 
ELISA kit (Standard Diagnostics), a sandwich ELISA for 
the qualitative detection of human Plasmodium pLDH. 
For quantitative assessment, blood was collected on the 
following days for each of the rodent malaria parasites: 
P. chabaudi AS: Day 7 (29 %), P. berghei ANKA: Day 4 
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(34  %), P. vinckei: Day 4 (32  %), and P. yoelii YM: Day 
5 (24  %). Recombinant pLDH supplied as the positive 
control in the kit was used to generate a standard curve 
dilution series with a starting concentration of 1320 ng/
mL in PBS or naïve mouse blood. Fifty microlitres of 
the samples (negative and positive control, standard 
curve and test samples) were tested in triplicate and 
the manufacturer’s instructions were followed. Plates 
were read on an xMark microplate spectrophotom-
eter (Biorad) at 450  nm, with a reference wavelength 
of 620  nm. The reading was completed within 30  min 
of the stop solution being added. The linear range was 
then logarithmically plotted to generate a linear equa-
tion to quantify levels of pLDH units in test samples. 
Positive wells were used to measure the concentration 
of pLDH unit, with the cut-off for positivity calculated 
as the mean  +  three standard deviations of the wells 
containing naïve mouse blood or PBS alone. The mean 
optical densities (ODs) were calculated for standards 
and used to plot a standard curve OD vs ng/mL recom-
binant pLDH antigen. The concentration of pLDH units 
in the samples was calculated from the optical density 
reading from the linear range of the standard curve (as 
in Fig.  2) such that 1 unit/mL in the test sample was 
equivalent to 1 ng/mL.
Visualization and quantification of luciferase activity 
in mice infected with Plasmodium berghei ANKA luciferase
Luciferase activity in P. berghei ANKA luc infected mice 
was visualized using an intensified-charge-coupled device 
(I-CCD) video camera of the  in vivo  Imaging System 
(IVIS 100, Xenogen) [8]. Mice were anaesthetized using 
the isofluorane anaesthesia system (XGI-8, Xenogen). 
Following this, mice were injected IP with d-luciferin 
dissolved in PBS (100  mg/kg of body weight; Synchem, 
Kassel, Germany) and measurements were performed 
within 5 min of injection. Bio-luminescence imaging was 
acquired with an exposure time of 60  s. Imaging data 
Table 1 pLDH protein sequence alignment analysis of dif-
ferent species of murine Plasmodium
pLDH sequence alignment using Clustal Omega
1 60




P. chabaudi chabaudi MAPKAKIVLVGSGMIGGVMATLIVQKNLGDV-
VMFDIVKDMPHGKALDTSHTNVMAYSNCQ
P. yoelii 17XNL MAPKAKIVLVGSGMIGGVMATLIVQKNLGDV-
VLFDIVKNMPHGKALDTSHTNVMAYSNCK
P. berghei ANKA MAPKAKIVLVGSGMIGGVMATLIVQKNLGDV-
VMFDIVKNMPHGKALDTSHTNVMAYSNCK
61 120





P. chabaudi chabaudi VSGSNTYDDLKGADVVIVTAGFTKAPGKSD-
KEWNRDDLLPLNNKIMIEIGGHIKKHCPHA
P. yoelii 17XNL VSGSNTYDDLKDADVVIVTAGFTKAPGKSD-
KEWNRDDLLPLNNKIMIEIGGHIKNNCPNA
P. berghei ANKA VSGSNTYDDLKDADVVIVTAGFTKAPGKSD-
KEWNRDDLLPLNNKIMIEIGGHIKNNCPNA
121 180




P. chabaudi chabaudi FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLG-
GVLDTSRLKYYISQKLNVCPRDVNAHIVG
P. yoelii 17XNL FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLG-
GVLDTSRLKYYISQKLNVCPRDVNAHIVG
P. berghei ANKA FIIVVTNPVDVMVQLLHQHSGVPKNKIVGLG-
GVLDTSRLKYYISQKLNVCPRDVNAHIVG
181 240




P. chabaudi chabaudi AHGNKMVLLKRYITVGGIPIQEFINNKKIS-
DQDLEAIFDRTINTALEIVNLHASPYVAPA
P. yoelii 17XNL AHGNKMVLLKRYITVGGIPLQEFINNKKIT-
DQELDAIFDRTVNTALEIVNLHASPYVAPA
P. berghei ANKA AHGNKMVLLKRYITVGGIPLQEFINNKKIT-
DQELDAIFDRTINTALEIVNLHASPYVAPA
241 300




P. chabaudi chabaudi AAIIEMAESYIRDLRKVLICSTLLEGQYGHK-
DIFAGTPLVIGGNGVEQVIELQLNADEKK
P. yoelii 17XNL AAIIEMAESYIRDLRKVLICSTLLEGQYGHK-
DIFAGTPLVIGGNGVEQVIELQLNADEKK
P. berghei ANKA AAIIEMAESYIRDLRKVLICSTLLEGQYGHK-
DIFAGTPLVIGGNGVEQVIELQLNADEKK
301 316
P. falciparum 3D7 (Pf LDH) [Accession ID XM_001349953.1] is the reference 
sequence. The bold letters indicate the dissimilarities in the amino acid 
sequences as compared to the pLDH amino acid sequence of P. falciparum. 
Plasmodium vinckei LDH [Accession ID XM_008624100.1]; P. chabaudi chabaudi 
LDH [Accession ID XM_740087.1]; P. yoelii 17XNL [Accession ID XM_719008.1]; P. 
berghei ANKA LDH [Accession ID XM_674309.1]
Table 1 continued
pLDH sequence alignment using Clustal Omega
P. falciparum 3D7 KFDEAIAETKRMKALA
P. vinckei HFDNAVAETARMKALI
P. chabaudi chabaudi KFDEAVAETSRMKALV
P. yoelii 17XNL KFDEAVAETSRMKALI
P. berghei ANKA KFDEAVAETSRMKALI
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were analysed using the living image (Xenogen) program. 
In asynchronous infections, measurements were per-
formed on different days at the same time.
Statistical analysis
Graphical and statistical analysis was performed using 
GraphPad Prism 6. All the datasets are presented as 
mean  ±  SE, unless stated otherwise. Non-linear stand-
ard curves were generated and the linear part of the 
curve was used for re-plotting three or more points in 
logarithmic scale. Logarithmic and arithmetic curves 
were both used for fitting a trend-line and obtaining an 
equation, which was used to calculate the concentration 
of pLDH units from the mean absorbance, for each test 
sample as described above. The limit of detection (LOD) 
was calculated as the lowest value in the dilution series 
that was significantly different from the negative control 
values. An ANOVA was performed to estimate the LOD. 
One-way ANOVA was used for the analyses presented 
in Figs. 1a and 2a, b. Correlation analyses between con-
centration of pLDH units, parasitaemia and log average 
radiance were determined using Pearson’s correlation 
analysis. A Pearson r value greater than 0.6 was consid-
ered as a strong correlation and shown in the appropriate 
figures. P values less than 0.05 were deemed significant 
for all statistical analyses. 
Results
Qualitative detection of pLDH in different blood 
components in mice infected with Plasmodium chabaudi 
AS
Due to the sequence similarity between the mouse and 
human Plasmodium LDH genes [45], this study utilized 
the human Plasmodium pLDH ELISA kit to assess its 
ability to detect murine Plasmodium pLDH. In a pilot 
study, pLDH was detected in both whole blood and 
serum obtained from a P. chabaudi AS infected mouse 































































































Fig. 1 a Qualitative detection of pLDH units in different blood components (undiluted) from a mouse infected with Plasmodium chabaudi AS. Indi-
vidual bars represent negative and positive control from the kit, whole blood obtained from a naïve or P. chabaudi AS-infected BALB/c mouse, serum 
obtained from a naïve or P. chabaudi AS-infected BALB/c mouse or whole blood obtained from a P. chabaudi AS-infected mouse which had been 
drug treated. b Representation of a non-linear standard curve to quantify pLDH units (ng/mL). Recombinant pLDH from the kit was serially diluted 
in both PBS and blood and plotted as log 10 concentration of recombinant pLDH vs the OD. The dotted line shows the linear range of the curve. 
Each sample was tested in triplicate. Error bars represent the mean ± SE of experimental replicates. ****P value <0.0001, ns not significant. One-way 
ANOVA was used to determine the statistical significance between groups
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<0.0001) (Fig.  1a). Whole blood and serum from both 
the naïve mouse and a mouse infected with P. chabaudi 
AS and drug cured (100 µL of malarone orally for 5 
days), did not have significant detectable pLDH units 
(Fig. 1a).
Generation of standard curves using recombinant pLDH
Standard curves were generated for quantitative assess-
ment of pLDH units in infected mice. Using the posi-
tive control (rec pLDH) from the commercial ELISA kit, 
serial dilutions were performed in both PBS and naïve 
mouse blood to establish standard curves. A representa-
tive standard curve from which the linear range was 
derived is shown in Fig. 1b. The linear range was approxi-
mately between 1.18 and 52.8 ng/mL.
Quantification of pLDH units in different species of murine 
Plasmodium
It was next established if this assay could be used to 
quantify pLDH units in the whole blood from mice 
infected with each of the four species of murine malaria. 
pLDH was detectable in whole blood obtained from mice 
infected with each of the rodent Plasmodium species 
(Fig. 2a). Despite a similar parasitaemia (24–34 %), pLDH 
units were significantly lower in mice infected with P. 
vinckei compared to the mice infected with P. chabaudi 
AS, P. berghei ANKA and P. yoelii YM.
Quantification of pLDH units in different parasitized blood 
components
It was then asked whether pLDH was limited to the red 
blood cell compartment or present both in the serum 
and pRBC. Blood samples obtained from mice infected 
with P. chabaudi AS and P. yoelii YM were separated 
into their components and the levels of pLDH units were 
determined in whole blood, serum and washed RBCs. 
Washed RBCs were prepared by washing whole blood 
thrice with PBS by centrifugation at 1500 rpm for 10 min. 
pLDH was detected in all three sample types, with whole 
blood showing higher levels of pLDH units compared to 
the serum and washed red blood cells (Fig. 2b).
Sensitivity of the pLDH assay in mice infected 
with Plasmodium chabaudi AS and Plasmodium berghei 
ANKA
Plasmodium chabaudi AS and P. berghei ANKA were 
selected for further studies. The limit of detection (LODs) 
















































































































Fig. 2 a Quantitative detection of pLDH units in whole blood of BALB/c mice infected with different murine Plasmodium species and b the mean 
concentration of pLDH units in different components of blood from BALB/c mice infected with Plasmodium chabaudi AS (29.7 %) and Plasmodium 
yoelii 17XNL (25 %). Percentages indicate the parasitaemia of the mice as determined by microscopy. Each sample was tested in triplicate. Error bars 
represent mean ± SE of experimental replicates. ****P value <0.0001, **P value <0.01, *P value <0.1, ns not significant. One-way ANOVA was used to 
determine the statistically significant difference between groups
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blood in naïve mouse blood. The LOD was approximately 
0.7  % parasitaemia for P. chabaudi AS and 0.05  % for 
P. berghei ANKA (Fig. 3).
Relationship between pLDH antigen levels 
and parasitaemia
The correlation between levels of pLDH units and 
peripheral blood parasitaemias during the course of 
infection was then assessed. Blood was obtained from 
mice every day post onset of patent parasitaemia. To 
ensure that the P. chabaudi-infected mice were not anae-
mic and to allow collection of a suitable volume of blood, 
a large group of mice (n = 20) were infected and divided 
into two cohorts. Blood from each cohort was collected 
on alternate days. A strong correlation (r = 0.9889) was 
observed (Fig. 4).
Relationship between pLDH units and total parasite 
bio‑burden in mice infected with Plasmodium berghei 
ANKA luciferase
To evaluate the assay as a measure of total parasite bio-
burden, BALB/c mice (n  =  16) were infected with P. 
berghei ANKA luciferase and parasitized whole blood 
was collected every alternate day from eight mice post 
visualization under the bio-illuminator (see “Methods”) 
(Fig. 5). Total radiance (Fig. 6a) was determined for each 
mouse throughout the infection. The concentration of 
pLDH units and parasitaemia were also determined 
(Fig.  6b, c). No correlation (r  =  0.2445) was observed 
between parasitaemia and pLDH units (Fig.  6d). How-
ever, a strong correlation (r  =  0.6922) was observed 
between the levels of pLDH units and log average radi-
ance (Fig. 6e).
Discussion
Current methods for the quantification of parasite lev-
els in blood include microscopy, qPCR and flow cytom-
etry, which are limited to detecting circulating parasites. 
These assays can be expensive and are unable to quan-
tify total parasite bio-burden. Sequestration of parasites 
in the cerebral regions, placenta and bone marrow leads 
to an underestimation of total parasite bio-burden when 
using these assays [47–49]. This study demonstrated that 
pLDH units correlate with total parasite bio-burden in 
murine malaria models. A human Plasmodium antibody-
based assay was used to quantify levels of pLDH in mice 
infected with different murine Plasmodium, including 
species that sequester in peripheral tissues or spleen, 
and established this assay as a measure of total parasite 
bio-burden.
This study investigated the use of a commercial human 
malaria ELISA kit to detect levels of pLDH units in the 
blood and serum of infected mice. Some differences are 
observed between P. falciparum and rodent malaria LDH 
sequences (see above); therefore, pLDH ‘units’ rather 
than amount of pLDH per se has been referred to when 
assessing rodent parasites, with one unit being defined as 
























Fig. 3 Limit of detection (LOD) of pLDH in BALB/c mice infected with 
a Plasmodium chabaudi AS (24 % parasitaemia) and b Plasmodium 
berghei ANKA (34 % parasitaemia). For this assay, infected whole 
blood was serially diluted in naïve mouse blood. ANOVA was used to 
estimate LOD. Each sample was tested in triplicate. Error bars repre-
sent mean ± SE of experimental replicates. The dotted line shows the 
limit of detection
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the OD equivalent of 1 ng of Pf LDH. pLDH units were 
detected at lower levels in P. vinckei-infected blood com-
pared to mice infected with other parasites. The assay 
was more sensitive for P. berghei ANKA, which could be 
due to less sequence variation in the region of the anti-
body-binding site compared to other parasites. However, 
as the binding site of the antibody is currently unknown, 
this could not be confirmed.
This study compared the levels of pLDH units to an 
established bio-burden assay with luciferase trans-
genic parasites [8, 13] to establish an economical, high 
throughput in vivo parasite bio-burden assay that is not 
reliant on the use of luminescent parasites or expensive 
equipment. A strong correlation was observed between 
the bio-luminescence and pLDH assays. It was of interest 
that a strong correlation between P. berghei peripheral 
parasitaemia and pLDH levels was not detected, which 
may be due to the presence of sequestered parasites as 
shown in the bio-luminescent images (Fig. 5). The strong 
correlation that was observed between P. chabaudi 
peripheral parasitaemia and pLDH levels (Fig. 4c) likely 
reflects the fact that this parasite is highly synchronous 
and blood samples were taken in the morning when the 
parasites are at the ring stage and in the periphery.
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Fig. 4 Correlation between the concentration of pLDH units and peripheral blood parasitaemia of BALB/c mice (n = 20) infected with Plasmodium 
chabaudi AS. a Mean parasitaemia in P. chabaudi AS infected mice. b Mean concentration of pLDH units in whole blood obtained from P. chabaudi 
AS infected mice. c Correlation between the mean concentration of pLDH and peripheral blood parasitaemia (r = 0.9889). Plus symbol indicates that 
the mice were culled. Error bars represent mean ± SE of biological replicates
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Conclusions
This study demonstrates the use of an established human 
malaria pLDH kit for detecting murine malaria para-
site bio-burden. pLDH was detected in four strains of 
murine Plasmodium. This assay permitted the estima-
tion of pLDH in different components of infected blood, 
thus, accounting for both circulating and sequestered 
parasites. This is confirmed by the strong correlation 
between the bio-luminescence and pLDH units during 
the initial parasite growth. Therefore, this assay provides 
an accurate assessment of parasite bio-burden in rodent 
malaria species. Furthermore, these results suggest that 
the pLDH assay can provide a valid estimate of total par-
asite bio-burden in malaria-infected patients.
Fig. 5 Visualization of luciferase-expressing Plasmodium berghei ANKA parasites in representative BALB/c mice. The distribution of parasites was 
visualized by measuring luciferase activity in animals by using an I-CCD video camera. Rainbow images show the relative level of luciferase activity 
ranging from low (blue), to medium (green), to high (yellow, red). The scale of total photon counts can be different between separate illustrations. 
The white arrows indicate a naïve mouse


























Conc. of pLDH (units/mL)
P value - 0.0289
r = 0.2445












































Conc. of pLDH (units/mL)
P value < 0.0001
r = 0.6922
Fig. 6 Relationship between pLDH units and total parasite bio-burden in mice (n = 16) infected with Plasmodium berghei ANKA luciferase. a Bio-
luminescence measured as average radiance [p/s/cmA2/sr] plotted on a logarithmic scale vs days post infection. b Mean concentration of pLDH 
units in whole blood obtained from infected mice days post infection. c Mean peripheral blood parasitaemia curves in infected mice as determined 
by microscopy. d Correlation between the pLDH units and mean parasitaemia, showing the coefficient correlation (r = 0.2445). e Correlation 
between the pLDH units and log average radiance, showing the coefficient correlation (r = 0.6992). Error bars represent mean ± SE of biological 
replicates. At day 1, the OD values for the infected mice were less than the control (naïve mouse blood)
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